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LETTERS TO THE EDITOR 
Hemochron Versus HemoTec Activated 
Coagulation Time Target Values 
During Percutaneous Transluminal 
Coronary Angioplasty 
We read with great interest he results of a study by Avendano and 
Ferguson (1) dealing with the target activated clotting time values 
determined by two different clot detecting systems. We agree with the 
authors on the main results of this study that activated clotting time 
results achieved by different machines cannot be used interchangeably, 
and further prospective research is needed to determine the level of 
correct anticoagulation. 
The two systems use different clot detecting systems, which at least 
partly explains the finding that the HemTec system usually detects a
shorter activated clotting time. The HemTec system detects the early 
appearance of the fibrin mesh, whereas the Hemochron system detects 
the time required for the formation of a firm clot capable of grabbing 
the magnet in a test tube and, hence, stops the timer. 
Our main criticism concerns the statistical method used in this 
study. Linear regression analysis is not an appropriate statistical test 
for comparing two methods measuring the same clinical variable. The 
correlation coefficient isa measure of the strength of linear association 
between two variables and does not show the level of agreement and 
contributes no information as to whether the two methods can be used 
interchangeably. The correlation coefficient also depends on the ran- 
dom measurement error and the range of measurements (2). One of 
the correct statistical tests for comparison of methods was published by 
Altman and Bland in 1983 (2). They suggested a simple calculation of 
the difference between the results achieved by the two methods and 
plotted this against heir mean value. The mean difference is the bias 
and the mean difference +2 SD is the limit of agreement. If this limit 
of agreement is smaller than the difference with clinical significance, 
then the two methods can be used interchangeably. The interpretation 
of the limit of agreement must depend on the clinical circumstances, 
and it is not possible to use statistics to define acceptable agreement. 
This statistical test has widely been used for comparison of methods 
studies (3-5). 
Statistical techniques provide the tools for assessing the validity of 
a finding. Use of the appropriate statistical method facilitates the 
correct interpretation of the results. It is a pity that >10 years after 
publication of an easy, clinically oriented statistical method, studies 
using incorrect statistical methods are still appearing in journals of 
international reputation. 
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Reply 
We appreciate the insightful comments of Varga et al. regarding the 
appropriate statistical techniques for comparing two different mea- 
surements of the same clinical variable. In response to their query, we 
have included an analysis of our data (1) using the technique published 
by Altman and Bland (2) (Fig. 1). This graph shows the difference 
between the two measurements plotted as a function of the mean of 
the two measurements. This type of analysis hows the variability of the 
two measurements over the entire range of application and is primarily 
useful for indicating whether one type of measurement can be used 
interchangeably with another. As is obvious from Figure 1 (and as 
stated in our original article), the Hemochron activated clotting time 
measurements tend to exceed HemoTec activated clotting time mea- 
surements; the degree of variability increases markedly after the 
administration f heparin. The implications are exactly the same as in 
the original article: Hemochron and HemoTec activated clotting time 
measurements cannot be used interchangeably. The regression equa- 
tion mentioned in the article was intended only to illustrate that a 
relation existed and should not be used as a basis to "predict" one 
activated clotting time measurement on the basis of measurements 
using the other technique. We agree that prospective data for both 
Figure 1. Difference between Hemochron and HemoTec measure- 
ments plotted as a function of the mean value of the two measure- 
ments. The degree of variability increases in the higher range of 
measurements, after the administration of heparin. 
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HemoTec and Hemochron activated clotting times will be necessary to
determine xactly what "adequate" anticoagulation is. 
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Congestive Heart Failure and 
Sodium Dichloroacetate 
I recently read with interest he excellent article by Bersin et al. (1) 
reporting on the metabolic and hemodynamic effects of sodium 
dichloroacetate in patients with congestive heart failure. Dichloroac- 
etate, in a dose of 50 mg/kg body weight, resulted in an increase in 
minute work of 12.3% (from 1.38 to 1.55 kg-m/m2), while at the same 
time myocardial oxygen consumption was reduced by 14.5% (from 19.3 
to 16.5 ml/min), resulting in a reported 28% increase in left ventricular 
mechanical efficiency. 
As the authors note, dichloroacetate stimulates pyruvate dehydro- 
genase activity by inhibiting pyruvate dehydrogenase kinase, enhancing 
glycolysis and increasing utilization of lactate, particularly in the 
myocardium. The concomitant inhibition of free fatty acid consump- 
tion leads to a shift of substrate utilization from predominantly free 
fatty acids--the usual preferred energy source of the myocardium--to 
glucose and lactate. The authors relate the improved mechanical 
efficiency of the heart to this shift in metabolic substrate. 
Two points, though, are unclear in this explanation. The authors 
attribute the higher efficiency of glucose to its higher respiratory 
quotient without explaining how the respiratory quotient affects energy 
utilization. Furthermore, they state that glucose and lactate generate 
more adenosine triphosphate (ATP) per mole of substrate (3.0 and 
3.2 mol, respectively) than fatty acids (yielding 2,8 tool of ATP per 
mole of substrate). However, fatty acids yield more ATP than glucose 
per mole of substrate. The complete oxidation of 1 mol of glucose 
yields 36 tool of ATP, not 3.0 tool (2), whereas the oxidation of I mol 
of palmitate, a 16-carbon fatty acid, yields 129 mol of ATP rather than 
2.8 (2). 
It appears more likely that the numbers 2.8 and 3.0 refer instead to 
the ratio, not of ATP to fuel substrate, but of ATP to oxygen 
requirements, a ratio that relates more directly to the issue of energy 
efficiency. For glucose, 6 mol of molecular oxygen (02) are necessary 
to yield 36 mol of ATP, giving an ATP/oxygen ratio (P/O) of 3.0 (2 
atoms of oxygen per molecule). For palmitate, its complete oxidation 
yields 16 mol of CO 2 and 129 tool of ATP (2). The respiratory quotient 
of 0.7 indicates that it requires, 16/0.7 or 22.9 mol of O2 to metabolize 
1 tool of palmitate, yielding a P/O of 129/(22.9 × 2) or 2.8. These 
calculations may explain how the respiratory quotient affects the 
mechanical efficiency of the heart, without directly affecting ATP 
generation, per se. 
One additional finding of this study requires further clarification. 
How does an increase in P/O from 2.8 to 3.0 (or even to 3.2) explain 
a 28% improvement in efficiency? It would seem that another mech- 
anism must be invoked. Is it possible that the metabolic shift caused by 
dichloroacetate, or a direct effect of dichloroacetate itself, could 
change the mechanical properties of the heart, allowing it to perform 
more work for a given level of ATP consumption'?. Perhaps dichloro- 
acetate does have vasodilating properties that effect his improvement 
in efficiency. 
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Reply 
In response to Koshkarian's letter regarding our article on dichloro- 
acetate in congestive heart failure (1), I have the following reply. 
Koshkarian raises two good points that require further clarification. 
First, he correctly points out that the ratios referred to in the Dis- 
cussion section of the article represent the adenosine triphosphate 
(ATP)/oxygen ratios (P/O ratio), which refer to the number of moles of 
ATP generated per mole of oxygen consumed, not per mole of substrate 
consumed as stated in the article. The respiratory quotients, on the 
other hand, refer to the number of moles of carbon dioxide produced 
per mole of oxygen consumed uring complete oxidation of substrate 
for aerobic respiration. The P/O ratio and the respiratory quotient of 
substrates for aerobic respiration tend to correlate such that substrates 
with the highest P/O ratios (glucose and lactate) tend to have the 
highest respiratory quotients. However, the P/O ratio most directly 
reflects the metabolic efficiency of a substrate. 
Because lactate has the highest P/O ratio (3.2:1), a shift in substrate 
utilization by the myocardium from predominantly free fatty acid 
utilization to lactate consumption should improve cardiac mechanical 
efficiency. However, Koshkarian's second point is that even a complete 
shift from free fatty acid consumption to lactate consumption would 
only be expected to increase cardiac mechanical efficiency by 14%, yet 
a 28% increase in cardiac mechanical efficiency was observed. There- 
fore, the observed change in mechanical efficiency cannot be com- 
pletely explained on the basis of a change in P/O ratios of substrate 
alone. A greater than expected change in mechanical efficiency ob- 
served with dichloroacetate may be explained by other effects that 
substrate and dichloroacetate have on cellular metabolism. 
In isolated rat hearts perfused with solutions containing either 
glucose or free fatty acids (Hexonate), Burkhoff et al. (2) observed a
greater than expected ecrease in myocardial efficiency based on the 
P/O ratios of substrate. Although a 10% reduction in myocardial 
efficiency for excitation-contraction c upling occurred as expected, the 
efficiency of basal metabolic function in the KCI arrested state was 
reduced by nearly 30%. This led Burkhoff et al. to conclude that the 
changes in P/O ratios in switching from glucose to Hexonate could only 
account for a portion of the change of myocardial efficiency measured. 
The difference between the expected and observed efficiencies ap- 
